Stem cells in patients with lung lesions (COVID-19)

Not Applicable

Recruiting

• Conditions: ung lesions; COVID-19; Lung Injury; Lung Diseases; Respiratory Tract Diseases; Thoracic Injuries; Coronavirus Infections; SARS Virus; Coronaviridae Infections; Betacoronavirus

• Registration Number: RPCEC00000322
• Lead Sponsor: Institute of Hematology and Immunology Dr. Jose Manuel Ballester Santovenia”

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-03
• Study Completion: 2021-02-15
• Results First Posted: 2021-05-12
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Patient who gives his informed consent.
2. Negative viral load by PCR.
3. Over 18 and under 75.
4. Lung damage evidenced by the criteria of radiological severity in COVID 19 on CT.

Exclusion Criteria

1. Anemia
2. Patients with contraindications to the use of IOR® LEUKOCIM.
3. Patients who have taken amiodarone in the last 3 months, which can cause pulmonary fibrosis.
4. Patients with malignant tumor in the last 5 years.
5. Patients with decompensated heart and kidney disease.
6. Patients with liver disease whose presence of enzyme values 2 times above the upper level of the range of normal values is demonstrated in the blood chemistry.
7. Patients who have ultrasound images that require further study for diagnosis.
8. Pregnant women
9. Patients with severe lung infection who need anti-infective treatment.
10. Patients with proven viral infections or positive serology.

Study & Design

• Study Type: Interventional
• Study Design: Not specified